Progestin regulation in tumor growth of female genital tract cancers.
The irregular response to progestins directly in tumor growth might be caused by dominant negative progesterone receptor (PR) mutants and the damage to PR-A expression. Progestin treatment as an anti-angiogenic therapy would be less effective in the PR-mutated tumors. Therefore, various anti-angiogenic inhibitors must be used in progestin-refractory and progestin-dependent tumors.
Fujimoto
J
J
Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu, Japan.
Sakaguchi
H
H
Misao
R
R
Hirose
R
R
Wen
H
H
Tamaya
T
T
D016228:Endothelial Growth Factors / Q000378:metabolism; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D005833:Genital Neoplasms, Female / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008222:Lymphokines / Q000378:metabolism; D009154:Mutation; D009376:Neoplasms, Hormone-Dependent / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000378:metabolism; D011372:Progestins / Q000235:genetics / Q000378:metabolism*; D020033:Protein Isoforms / Q000378:metabolism; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism*; D013939:Thymidine Phosphorylase / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D011372:Progestins; D020033:Protein Isoforms; D011980:Receptors, Progesterone; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D013939:Thymidine Phosphorylase